High HER2 expression correlates with response to the combination of lapatinib and trastuzumab

• Published in: Clinical cancer research Vol. 21; no. 3; pp. 569 - 576
• Main Authors: Scaltriti, Maurizio, Nuciforo, Paolo, Bradbury, Ian, Sperinde, Jeff, Agbor-Tarh, Dominique, Campbell, Christine, Chenna, Ahmed, Winslow, John, Serra, Violeta, Parra, Josep Lluis, Prudkin, Ludmila, Jimenez, José, Aura, Claudia, Harbeck, Nadia, Pusztai, Lajos, Ellis, Catherine, Eidtmann, Holger, Arribas, Joaquin, Cortes, Javier, de Azambuja, Evandro, Piccart, Martine, Baselga, José
• Format: Journal Article
• Language: English
• Published: United States 01.02.2015
• Subjects: Antibodies, Monoclonal, Humanized - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biopsy; Breast Neoplasms - drug therapy; Breast Neoplasms - genetics; Breast Neoplasms - metabolism; Breast Neoplasms - mortality; Breast Neoplasms - pathology; Female; Gene Expression; Humans; Neoadjuvant Therapy; Quinazolines - administration & dosage; Receptor, ErbB-2 - genetics; Receptor, ErbB-2 - metabolism; Trastuzumab; Treatment Outcome
• ISSN: 1078-0432; 1557-3265
• DOI: 10.1158/1078-0432.CCR-14-1824

Expression of p95HER2 has been associated with resistance to trastuzumab-based therapy in patients with metastatic breast cancer. Conversely, high levels of HER2 have been linked with increased clinical benefit from anti-HER2 therapy. In this work, we aimed to investigate whether the levels of p95HER2 and HER2 can predict response to anti-HER2 therapy in patients with breast cancer. We measured p95HER2 and HER2 by VeraTag and HERmark, respectively, in primary tumors of patients enrolled in the neoadjuvant phase III study NeoALTTO and correlated these variables with pathologic complete response (pCR) and progression-free survival (PFS) following lapatinib (L), trastuzumab (T), or the combination of both agents (L+T). A positive correlation between p95HER2 and HER2 levels was found in the 274 cases (60%) in which quantification of both markers was possible. High levels of these markers were predictive for pCR, especially in the hormone receptor (HR)-positive subset of patients. High HER2 expression was associated with increased pCR rate upon L+T irrespective of the HR status. To examine whether the levels of either p95HER2 or HER2 could predict for PFS in patients treated with lapatinib, trastuzumab or L+T, we fit to the PFS data in Cox models containing log2(p95HER2) or log2(HER2). Both variables correlated with longer PFS. Increasing HER2 protein expression correlated with increased benefit of adding lapatinib to trastuzumab. HER2 expression is a stronger predictor of pCR and PFS than p95HER2 for response to lapatinib, trastuzumab and, more significantly, L+T.